CVS
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
CVS Health Corp.
- Nom
- CVS Health Corp.
- Secteur
- Healthcare
- Industrie
- Medical - Healthcare Plans
- Bourse
- NYSE
- Capitalisation
- $119.5B
- Employés
- 259,500
- PDG
- J. David Joyner
- Site web
- https://www.cvshealth.com
- Marché
- ALHCCICNCELVHUMMOH
CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-06-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-05-01 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-04-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-01-13 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2025-11-21 | Dwight Evans | Sale (Partial) | $1,001 - $15,000 |
| 2025-11-21 | Dwight Evans | Sale (Full) | $1,001 - $15,000 |
| 2025-10-31 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-09-23 | Val Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-08-08 | Adam Smith | Sale (Full) | $1,001 - $15,000 |
| 2025-05-15 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-04-10 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2025-04-01 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-02-25 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-01-31 | French Hill | Sale (Full) | $15,001 - $50,000 |
| 2025-01-24 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-01-15 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-01-13 | Michael T. McCaul | Purchase | $100,001 - $250,000 |
| 2024-12-11 | Julia Letlow | Sale (Full) | $1,001 - $15,000 |
| 2024-10-29 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2024-10-25 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2024-10-24 | Thomas Suozzi | Sale (Full) | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-06-27 | Earl Blumenauer | Sale (Full) | $1,001 - $15,000 |
| 2024-06-05 | Michael T. McCaul | Purchase | $1,001 - $15,000 |
| 2024-05-17 | William R. Keating | Sale (Full) | $1,001 - $15,000 |
| 2024-05-07 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-02-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-10-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-12 | Michael T. McCaul | Purchase | $1,001 - $15,000 |
| 2023-09-12 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2023-09-06 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-08-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-06-29 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-06-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-06-22 | Dwight Evans | Purchase | $1,001 - $15,000 |
| 2023-06-08 | William R. Keating | Sale (Full) | $1,001 - $15,000 |
| 2023-05-26 | Zoe Lofgren | Sale (Full) | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-19 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-05-17 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2023-05-17 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-05-17 | Michael T. McCaul | Purchase | $100,001 - $250,000 |
| 2023-05-17 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2023-05-12 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2023-05-12 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-05-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-04 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-04-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-04-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-04-10 | Daniel Goldman | Sale | $50,001 - $100,000 |
| 2023-03-24 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-03-14 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-03-06 | Daniel Goldman | Purchase | $15,001 - $50,000 |
| 2023-02-14 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-02-10 | Ro Khanna | Purchase | $50,001 - $100,000 |
| 2023-01-31 | Daniel Goldman | Purchase | $1,001 - $15,000 |
| 2023-01-25 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2023-01-25 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2023-01-25 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2023-01-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-01-09 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-01-05 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2023-01-05 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-11-29 | Thomas Suozzi | Sale (Full) | $15,001 - $50,000 |
| 2022-11-04 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-07 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-12 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-07-19 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-07-15 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2022-06-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-06-21 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-06-21 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-06-21 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-05 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-04-25 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-04-25 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-04-25 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-04-05 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-04-05 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-04-05 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-03-16 | John Henry Rutherford | Sale (Full) | $1,001 - $15,000 |
| 2022-03-09 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2022-03-09 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2021-11-10 | Thomas Suozzi | Sale (Partial) | $15,001 - $50,000 |
| 2021-07-01 | Richard Ray Larsen | Sale (Full) | $1,001 - $15,000 |
| 2021-06-04 | Thomas Suozzi | Sale (Partial) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
CVS presents a moderate earnings catalyst with a history of positive surprises ahead of its Q3 2026 call, but the underlying financial health is critically weak, with near-zero net margins, a debt/EBITDA of 8.6x, and a…
The first sentence of the analysis written for CVS on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Supports a bullish reading. 3 purchase disclosures year to date
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Pulls against a bullish reading. Current ratio 0.84 · operating margin 2.6%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 13.8% | 13.8% | 15.2% | 16.9% | 17.8% | |
| Ebit Margin | 1.3% | 2.4% | 3.9% | 2.5% | 4.5% | |
| Ebitda Margin | 2.5% | 3.7% | 5.1% | 3.8% | 6.0% | |
| Operating Profit Margin | 2.6% | 2.3% | 3.8% | 2.5% | 4.6% | |
| Pretax Profit Margin | 0.5% | 1.6% | 3.1% | 1.8% | 3.6% | |
| Continuous Operations Profit Margin | 0.4% | 1.2% | 2.3% | 1.3% | 2.7% | |
| Net Profit Margin | 0.4% | 1.2% | 2.3% | 1.3% | 2.7% | |
| Bottom Line Profit Margin | 0.4% | 1.2% | 2.3% | 1.3% | 2.7% | |
| Current Ratio | 0.842 | 0.811 | 0.857 | 0.945 | 0.885 | |
| Quick Ratio | 0.625 | 0.597 | 0.629 | 0.670 | 0.623 | |
| Solvency Ratio | 0.034 | 0.052 | 0.073 | 0.055 | 0.079 | |
| Cash Ratio | 0.096 | 0.101 | 0.103 | 0.186 | 0.139 | |
| Price To Earnings Ratio | 56.686 | 12.265 | 12.166 | 28.325 | 17.193 | |
| Price To Earnings Growth Ratio | -0.918 | -0.281 | 0.125 | -0.627 | 1.812 | |
| Forward Price To Earnings Growth Ratio | -0.918 | -0.281 | 0.125 | -0.627 | 1.812 | |
| Price To Earnings Diluted Ratio | 57.094 | 12.265 | 12.204 | 28.586 | 17.338 | |
| Price To Earnings Diluted Growth Ratio | -0.921 | -0.282 | 0.124 | -0.632 | 1.932 | |
| Price To Book Ratio | 1.337 | 0.748 | 1.327 | 1.711 | 1.812 | |
| Price To Sales Ratio | 0.250 | 0.152 | 0.284 | 0.379 | 0.466 | |
| Price To Free Cash Flow Ratio | 12.879 | 8.934 | 9.761 | 9.090 | 8.642 | |
| Price To Operating Cash Flow Ratio | 9.451 | 6.206 | 7.557 | 7.558 | 7.450 | |
| Debt To Assets Ratio | 0.359 | 0.327 | 0.318 | 0.310 | 0.326 | |
| Debt To Equity Ratio | 1.244 | 1.097 | 1.038 | 0.990 | 1.012 | |
| Debt To Capital Ratio | 0.554 | 0.523 | 0.509 | 0.497 | 0.503 | |
| Long Term Debt To Capital Ratio | 0.492 | 0.445 | 0.434 | 0.414 | 0.409 | |
| Financial Leverage Ratio | 3.471 | 3.351 | 3.266 | 3.194 | 3.104 | |
| Working Capital Turnover Ratio | -26.856 | -27.317 | -47.328 | -55.660 | -43.446 | |
| Operating Cash Flow Ratio | 0.120 | 0.108 | 0.170 | 0.233 | 0.269 | |
| Operating Cash Flow Sales Ratio | 0.026 | 0.024 | 0.038 | 0.050 | 0.063 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.734 | 0.695 | 0.774 | 0.831 | 0.862 | |
| Debt Service Coverage Ratio | 1.059 | 1.393 | 2.734 | 2.666 | 2.233 | |
| Interest Coverage Ratio | 3.330 | 2.879 | 5.170 | 3.478 | 5.318 | |
| Short Term Operating Cash Flow Coverage Ratio | 1.833 | 1.586 | 4.517 | 9.098 | 4.344 | |
| Operating Cash Flow Coverage Ratio | 0.114 | 0.110 | 0.169 | 0.229 | 0.240 | |
| Capital Expenditure Coverage Ratio | 3.757 | 3.275 | 4.430 | 5.932 | 7.248 | |
| Dividend Paid And Capex Coverage Ratio | 1.708 | 1.480 | 2.178 | 2.871 | 3.550 | |
| Dividend Payout Ratio | 1.921 | 0.731 | 0.375 | 0.674 | 0.328 | |
| Enterprise Value Multiple | 18.825 | 9.563 | 9.488 | 14.583 | 11.563 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 13.8% | ▼-0.0% | ▼-1.7% |
| Ebit Margin | 1.3% | ▼-1.1% | ▼-1.6% |
| Ebitda Margin | 2.5% | ▼-1.2% | ▼-1.8% |
| Operating Profit Margin | 2.6% | ▲0.3% | ▼-0.6% |
| Pretax Profit Margin | 0.5% | ▼-1.1% | ▼-1.6% |
| Continuous Operations Profit Margin | 0.4% | ▼-0.8% | ▼-1.2% |
| Net Profit Margin | 0.4% | ▼-0.8% | ▼-1.2% |
| Bottom Line Profit Margin | 0.4% | ▼-0.8% | ▼-1.2% |
| Current Ratio | 0.842 | ▲0.031 | ▼-0.026 |
| Quick Ratio | 0.625 | ▲0.028 | ▼-0.004 |
| Solvency Ratio | 0.034 | ▼-0.018 | ▼-0.024 |
| Cash Ratio | 0.096 | ▼-0.005 | ▼-0.029 |
| Price To Earnings Ratio | 56.686 | ▲44.421 | ▲31.359 |
| Price To Earnings Growth Ratio | -0.918 | ▼-0.637 | ▼-0.940 |
| Forward Price To Earnings Growth Ratio | -0.918 | ▼-0.637 | ▼-0.940 |
| Price To Earnings Diluted Ratio | 57.093 | ▲44.828 | ▲31.596 |
| Price To Earnings Diluted Growth Ratio | -0.920 | ▼-0.638 | ▼-0.965 |
| Price To Book Ratio | 1.337 | ▲0.589 | ▼-0.050 |
| Price To Sales Ratio | 0.250 | ▲0.099 | ▼-0.056 |
| Price To Free Cash Flow Ratio | 12.879 | ▲3.945 | ▲3.018 |
| Price To Operating Cash Flow Ratio | 9.451 | ▲3.245 | ▲1.807 |
| Debt To Assets Ratio | 0.358 | ▲0.031 | ▲0.030 |
| Debt To Equity Ratio | 1.244 | ▲0.147 | ▲0.168 |
| Debt To Capital Ratio | 0.554 | ▲0.031 | ▲0.037 |
| Long Term Debt To Capital Ratio | 0.492 | ▲0.047 | ▲0.053 |
| Financial Leverage Ratio | 3.471 | ▲0.120 | ▲0.194 |
| Working Capital Turnover Ratio | -26.856 | ▲0.461 | ▲13.265 |
| Operating Cash Flow Ratio | 0.120 | ▲0.012 | ▼-0.060 |
| Operating Cash Flow Sales Ratio | 0.026 | ▲0.002 | ▼-0.014 |
| Free Cash Flow Operating Cash Flow Ratio | 0.734 | ▲0.039 | ▼-0.045 |
| Debt Service Coverage Ratio | 1.059 | ▼-0.334 | ▼-0.958 |
| Interest Coverage Ratio | 3.330 | ▲0.451 | ▼-0.705 |
| Short Term Operating Cash Flow Coverage Ratio | 1.833 | ▲0.247 | ▼-2.443 |
| Operating Cash Flow Coverage Ratio | 0.114 | ▲0.004 | ▼-0.059 |
| Capital Expenditure Coverage Ratio | 3.757 | ▲0.482 | ▼-1.171 |
| Dividend Paid And Capex Coverage Ratio | 1.708 | ▲0.228 | ▼-0.650 |
| Dividend Payout Ratio | 1.921 | ▲1.190 | ▲1.115 |
| Enterprise Value Multiple | 18.825 | ▲9.262 | ▲6.020 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $100.55B | $56.52B | $101.46B | $122.27B | $136.07B | |
| Enterprise value | $185.63B | $130.85B | $172.65B | $180.05B | $202.66B | |
| EV / Sales | 0.46x | 0.35x | 0.48x | 0.56x | 0.69x | |
| EV / Op. cash flow | 17.45x | 14.37x | 12.86x | 11.13x | 11.10x | |
| EV / Free cash flow | 23.78x | 20.68x | 16.61x | 13.39x | 12.87x | |
| EV / EBITDA | 18.82x | 9.56x | 9.49x | 14.58x | 11.56x | |
| Net debt / EBITDA | 8.63x | 5.43x | 3.91x | 4.68x | 3.80x | |
| Current ratio | 0.84x | 0.81x | 0.86x | 0.94x | 0.89x | |
| Income quality | 6.16x | 1.99x | 1.60x | 3.74x | 2.29x | |
| Graham number | $43 | $70 | $93 | $63 | $88 | |
| Graham net-net | -$107 | -$103 | -$98 | -$84 | -$89 | |
| Tax burden | 82.8% | 75.0% | 74.7% | 73.9% | 75.9% | |
| Interest burden | 40.6% | 67.5% | 80.8% | 71.8% | 80.8% | |
| Working capital | -$13.98B | -$15.96B | -$11.33B | -$3.79B | -$7.80B | |
| Invested capital | $125.06B | $131.57B | $139.61B | $129.91B | $132.37B | |
| Return on assets | 0.7% | 1.8% | 3.3% | 1.9% | 3.4% | |
| Operating ROA | 4.0% | 3.4% | 5.8% | 3.4% | 5.7% | |
| Return on tangible assets | 1.2% | 3.4% | 6.5% | 3.4% | 6.4% | |
| Return on equity | 2.4% | 6.1% | 10.9% | 6.0% | 10.7% | |
| Return on invested capital | 4.7% | 3.6% | 5.9% | 3.6% | 5.9% | |
| Return on capital employed | 6.0% | 5.1% | 8.1% | 5.0% | 8.1% | |
| Earnings yield | 1.8% | 8.2% | 8.2% | 3.5% | 5.9% | |
| Free cash flow yield | 7.8% | 11.2% | 10.2% | 11.0% | 11.6% | |
| Capex / Op. cash flow | 26.6% | 30.5% | 22.6% | 16.9% | 13.8% | |
| Capex / Depreciation | 61.5% | 60.5% | 69.4% | 64.6% | 56.2% | |
| Capex / Sales | 0.7% | 0.7% | 0.8% | 0.8% | 0.9% | |
| SG&A / Sales | 0.0% | 11.1% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.1% | 0.1% | 0.2% | 0.1% | 0.2% | |
| Intangibles / Total assets | 42.5% | 46.8% | 48.3% | 45.1% | 46.4% | |
| Days sales outstanding | 36d | 36d | 36d | 31d | 31d | |
| Days payables outstanding | 63d | 18d | 18d | 20d | 19d | |
| Operating cycle | 56d | 56d | 58d | 57d | 58d | |
| Cash conversion cycle | -6d | 38d | 40d | 37d | 38d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+77.9%EV / Sales ▲+31.5%EV / EBITDA ▲+96.8%EV / Op. cash flow ▲+3.080Earnings yield ▼-0.064Graham number ▼-27.175
Profitability
Return on equity ▼-0.038Return on assets ▼-0.011Return on invested capital ▲+0.011Return on capital employed ▲+0.010Operating ROA ▲+0.007Income quality ▲+4.171Tax burden ▲+0.077
Efficiency
Days sales outstanding ▲+0.407Days payables outstanding ▲+44.470Operating cycle ▲+0.105Cash conversion cycle ▼-44.365Capex / Sales -0.000R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.031Net debt / EBITDA ▲+3.195Working capital ▲+1986000000.000Invested capital ▼-6504000000.000Intangibles / Total assets ▼-0.043
Change over 5 years
Valuation
Market cap ▼-26.1%EV / Sales ▼-33.5%EV / EBITDA ▲+62.8%EV / Op. cash flow ▲+6.353Earnings yield ▼-0.041Graham number ▼-44.966
Profitability
Return on equity ▼-0.083Return on assets ▼-0.028Return on invested capital ▼-0.012Return on capital employed ▼-0.020Operating ROA ▼-0.017Income quality ▲+3.871Tax burden ▲+0.068
Efficiency
Days sales outstanding ▲+5.585Days payables outstanding ▲+43.440Operating cycle ▼-1.165Cash conversion cycle ▼-44.604Capex / Sales ▼-0.002R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.043Net debt / EBITDA ▲+4.828Working capital ▼-6179000000.000Invested capital ▼-7302000000.000Intangibles / Total assets ▼-0.039
Employee count
Peer market caps
Recent news
- 2026-10-05 CVS Health Corporation $CVS Stock Position Trimmed by Park National Corp OH Park National Corp OH reduced its stake in CVS Health Corporation (NYSE: CVS) by 4.4% during the third quarter, according to its most recent filing with the SEC. The fund owned 132,587 shares of the pharmacy operator''s stock after selling 6,031 shares during the quarter. Park National Corp OH''s holdings in CVS Health
- 2026-10-05 Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report? CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 2026-10-05 CVS Health Corporation $CVS Stock Acquired by Argent Capital Management LLC Argent Capital Management LLC grew its position in shares of CVS Health Corporation (NYSE: CVS) by 50.4% during the third quarter, according to its most recent filing with the SEC. The firm owned 238,110 shares of the pharmacy operator''s stock after acquiring an additional 79,822 shares during the period. Argent Capital Management LLC''s
- 2026-10-05 Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
- 2026-10-05 CVS Health to hold third quarter 2026 earnings conference call WOONSOCKET, R.I., Oct. 5, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) will hold a conference call with analysts and investors on Wednesday, November 4, 2026, at 8:00 a.m.
- 2026-10-03 Aetna 2027 Medicare plans offer reliable, affordable access to care & member support Aetna 2027 Medicare plans offer reliable, affordable access to care and member supportPR NewswireWOONSOCKET, R.I., Oct. 3, 2026Plans designed to provide member va
- 2026-10-03 Aetna 2027 Medicare plans offer reliable, affordable access to care & member support Plans designed to provide member value and access to care: $0 copays on Tier 1 drugs and covered vaccines at in-network pharmacies* $0 copays for annual physicals, colonoscopies and mammograms at in-network providers $0 copays for annual Healthy Home Visit from a licensed Signify Health clinician Dental, vision and hearing benefits A continued focus on affordability, quality care and preserving the benefits that matter most to members through an expanded HMO portfolio and market-leading coverage of generic drugs Targeted care for high-needs members with chronic conditions and those dually eligible for Medicare and Medicaid Award-winning guidance and support for our members delivered through our dedicated service teams and market-leading digital tools WOONSOCKET, R.I., Oct. 3, 2026 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), today announced our 2027 Medicare products with choices designed to support older adults with a wide range of health needs, providing reliable benefits that enable affordability and access to quality care.
- 2026-10-01 These 3 Dividend Stocks Yield Less Than 10-Year Treasuries Over 5%. Here''s Why They Are Better Buys Anyway. Treasuries pay more today, but these three healthcare dividend payers offer something Treasuries can''t: growth in both the payout and the stock.
- 2026-09-30 CVS Health declares quarterly dividend WOONSOCKET, R.I., Sept. 30, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation.
- 2026-09-28 CVS Health (CVS) Falls More Steeply Than Broader Market: What Investors Need to Know The latest trading day saw CVS Health (CVS) settling at $87.85, representing a -1.44% change from its previous close.